Sign in
Taking people in United StatesPhase 2

Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD)

Key facts

Who runs it
Cedars-Sinai Medical Center
Where
Indianapolis, Los Angeles, New Orleans, and Sacramento, United StatesSee the 4 sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
80 people, planned
Started
20 Apr 2022
Expected to end
31 Dec 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Fluticasone Propionate 93 MCG/1 ACTUATION Nasal Spray
  • Placebo Nasal Spray
Record updated
11 March 2026

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Age greater than or equal to 18 years old, <80 years old
  • Chronic Eustachian tube dysfunction defined as:; Symptoms in one or both ears > 3 months AND; ETDQ-7 score >14.5 AND; Type B, C, or As tympanometry
  • Female subjects of childbearing potential must have a negative urine pregnancy test at screening and throughout the study duration

Who cannot take part

  • Use of any additional intranasal medication
  • Any history of temporomandibular disorder or prior surgery to the temporomandibular joint
  • Known history of otologic surgery (excluding myringotomy or myringotomy tubes)
  • Tympanic membrane perforation
  • Any history of head and neck cancer
  • Any history of head and neck irradiation
  • Any medical condition that the investigator deems inappropriate for enrollment
  • Age <18 years old
  • Adhesive otitis media
  • Cholesteatoma or significant retraction pocket
  • Middle ear effusion
  • Nasopharyngeal tumor

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

This trial is currently available in United States.

  • Indiana UniversityIndianapolis, United StatesContact: Elisa Illing, MDTaking people
  • Cedars-Sinai Medical CenterLos Angeles, United StatesContact: Missael VasquezTaking people
  • Ochsner Health SystemNew Orleans, United StatesContact: Edward McCoul, MDTaking people
  • Sacramento Ear, Nose & ThroatSacramento, United StatesContact: Rose KhalatyanTaking people

About the trial

What the trial wants to find out

Intranasal nasal steroid sprays are the mainstay of treatment for chronic Eustachian tube dysfunction despite having little supportive evidence in the literature. A novel, commercially available nasal spray delivery system is available now for fluticasone that improves its delivery to the nasopharynx. The hypothesis of this study is that fluticasone using the novel spray system is effective for Eustachian tube dysfunction (ETD).

The 2 groups in the trial

  • Arm 1 (Placebo)Placebo, for comparison

    Arm 1 (placebo) will get placebo spray per day.

    Treatment: Placebo Nasal Spray

  • Arm 2 (EDS-FLU)Existing treatment, for comparison

    Arm 2 (EDS-FLU) will get 744 mcg of fluticasone propionate per day.

    Treatment: Fluticasone Propionate 93 MCG/1 ACTUATION Nasal Spray

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD) in a Multi-center, Double-Blinded, Placebo-controlled Trial
Criteria questions
Built from NCT05275686, who can take part
Record updated
11 March 2026